EP3389420B1 - Strength enhancers and method of achieving strength enhancement in an electronic vapor device - Google Patents

Strength enhancers and method of achieving strength enhancement in an electronic vapor device Download PDF

Info

Publication number
EP3389420B1
EP3389420B1 EP16822652.0A EP16822652A EP3389420B1 EP 3389420 B1 EP3389420 B1 EP 3389420B1 EP 16822652 A EP16822652 A EP 16822652A EP 3389420 B1 EP3389420 B1 EP 3389420B1
Authority
EP
European Patent Office
Prior art keywords
acid
percent
vaporization formulation
concentration
vapor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP16822652.0A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3389420A1 (en
Inventor
Adam Anderson
David Kane
Weiling LI
Peter Lipowicz
Douglas OLIVERI
Mark RUSYNIAK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Philip Morris Products SA
Original Assignee
Philip Morris Products SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57749910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3389420(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Philip Morris Products SA filed Critical Philip Morris Products SA
Priority to PL16822652T priority Critical patent/PL3389420T3/pl
Publication of EP3389420A1 publication Critical patent/EP3389420A1/en
Application granted granted Critical
Publication of EP3389420B1 publication Critical patent/EP3389420B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/24—Treatment of tobacco products or tobacco substitutes by extraction; Tobacco extracts
    • A24B15/241—Extraction of specific substances
    • A24B15/243—Nicotine
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/302—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances by natural substances obtained from animals or plants
    • A24B15/303—Plant extracts other than tobacco
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/32—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances by acyclic compounds
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/34—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a carbocyclic ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/42—Treatment of tobacco products or tobacco substitutes by chemical substances by organic and inorganic substances
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/40—Constructional details, e.g. connection of cartridges and battery parts
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/10—Devices using liquid inhalable precursors

Definitions

  • the present invention relates generally to a pre-vaporization formulation for e-vaping devices. More particularly, the present invention relates to strength enhancers in pre-vaporization formulations.
  • Electronic vaping devices are used to vaporize a pre-vaporization formulation such as, for example, a liquid material, into a vapor in order for an adult vaper to inhale the vapor.
  • E-vaping devices typically include a heater which vaporizes the pre-vaporization formulation to produce the vapor.
  • An e-vaping device may include several e-vaping elements including a power source, a cartridge or e-vaping tank including the heater, and a reservoir holding the pre-vaporization formulation.
  • a tobacco-based smoking article produces a vapor known to create a desired sensory experience for adult smokers, including a low to moderate harshness response in the throat and a perceived warmth or strength in the chest of an adult smoker.
  • the harshness of the vapor which is typically understood as the sensation experienced in the throat of an adult vaper
  • the strength of the vapor which is typically understood as the sensation experienced in the chest of the adult vaper
  • an e-vaping device is harsher than a tobacco-based product, but has a strength that is lower than the strength of the tobacco-based product.
  • the harshness of the e-vaping device increases.
  • EP 2 862 454 A1 discloses a liquid composition for an electronic cigarette comprising glycerol as a TRP modulator and at least one TRP agonist / activator selected from 6-paradole and analogues, wherein interaction of the TRP modulator and at least one TRP agonist / activator results in chemosensory imitation of inhaled cigarette smoke, and wherein the liquid composition contains no nicotine.
  • 6-paradole and analogues comprise 1'-acetoxychavicol acetate and analogues, isothiocyanates and analogues, camphor and analogues, grains of paradise, thymol and analogues and ethanol.
  • One or more extracts comprising black pepper, horseradish, garlic, paprika, cinnamon, mint and acetic acid and citric acid may be used as another TRP agonist / activator in the liquid composition.
  • WO 2009/001085 A2 discloses an inhalable composition comprising at least 22 volume % oxygen, and nicotine or a nicotine derivative or salt.
  • the composition may comprise a solvent.
  • suitable solvents include propylene glycol, polypropylene glycol, polyethylene glycol (PEG), glycerol, ethanol and propanol.
  • the composition may also include an antioxidant. Suitable antioxidants include phenolic compounds, flavonols, flavanones, flavones, flavon-3-ols, anthocyanins (flavonals), isoflavones , coumestans, carotenes, xanthophylls, phytosterols and tocopherols.
  • Suitable phenolic compounds include monophenols, apiole, carnosol, carvacrol, dillapiole, rosemarinol and flavonoids (polyphenols).
  • Suitable coumestans (phytoestrogens) include coumestrol, ellagic acid, gallic acid, salicylic acid, tannic acid, vanillin, capsaicin, curcumin (oxidizes to vanillin), hydroxycinnamic acids, caffeic acid, chlorogenic acid, cinnamic acid, ferulic acid, coumarin, lignans (phytoestrogens), silymarin and matairesinol , secoisolariciresinol, terpenes (isoprenoids) and carotenoids (tetraterpenoids).
  • the composition may also include an essential oil.
  • suitable essential oils include geraniol, nerol, phenethyl alcohol, eugenol methyl ether, farrnesol, linalool, citronellol, rose, cuminaldehyde, zingiberene, Farnesol, verbenone, nootkatone, myrcene, menthol citral, citronellal, pinene, thymol and menthone.
  • compositions for delivery to the respiratory tract of a subject comprising: a liquid including an agent, the agent being an activator of a TRPV3 channel, and the agent including a terpenoid compound.
  • the terpenoid compound may include one or more of camphor, carvacrol, thymol and incensole of either a plant or synthetic origin.
  • US 2015/038576 A1 discloses exemplary compositions comprising propylene glycol.
  • the present invention relates to an e-vaping device configured to achieve a desirable balance of strength and harshness, where strength is increased without increasing harshness.
  • the present invention relates to an e-vaping device that is configured to provide a perceived sensory experience for adult vapers that is similar to the sensory experience enjoyed while smoking a tobacco-based cigarette.
  • the present invention relates to an e-vaping device that is configured to provide a sensory experience including levels of harshness in the throat and perceived strength or warmth in the chest that are similar to those experienced when smoking a tobacco-based product.
  • the strength of the e-vaping product may be increased without increasing the harshness thereof.
  • the present invention relates to a pre-vaporization formulation for an e-vaping device including a mixture of a vapor former and one or more strength enhancers or additives.
  • a pre-vaporization formulation for an e-vaping device comprising: a vapor former including at least one of propylene glycol and glycerol; nicotine; one or more acids in a concentration of between 0.1 percent and 5 percent; and an additive including at least one of carvacrol, thymol, monomenthyl succinate, N-(2-hydroxyethyl)-2,3-dimethyl-2-isopropyl butanamide.
  • an e-vaping device comprising: a cartomizer including a reservoir holding a pre-vaporization formulation, a mouth-end piece, and a heater configured to heat the pre-vaporization formulation; and a power supply section connected to the cartomizer and including a puff sensor configured to sense a puff taking place at the mouth-end piece, and a power source configured to supply power to the heater; wherein the pre-vaporization formulation includes: a vapor former including a combination of propylene glycol and glycerol; nicotine; one or more acids in a concentration of between 0.1 percent and 5 percent; and an additive including at least one of carvacrol, thymol, monomenthyl succinate, N-(2-hydroxyethyl)-2,3-dimethyl-2-isopropyl butanamide.
  • the pre-vaporization formulation may include water.
  • the pre-vaporization formulation may be a liquid formulation.
  • the pre-vaporization formulation comprises nicotine.
  • the one or more strength enhancers or additives include at least one of carvacrol, thymol, monomenthyl succinate, N-(2-hydroxyethyl)-2,3-dimethyl-2-isopropyl butanamide.
  • the one or more strength enhancers or additives may include at least one of cinnamaldehyde, menthone, eugenol, zingerone or vanillyacetone, and gingerol.
  • the one or more strength enhancers or additives may further include at least one of capsicum, allyl isothiocyanate, piperine, isoeugenol and menthol.
  • the above compounds as well as others can be found in extracts such as, for example, horseradish oil, garlic extract, onion oil, black pepper, cayenne pepper, ginger oil, thyme oil, cinnamon bark oil, turmeric, fenugreek, cardamom, rosemary extract, grapefruit oil and andrographis extract.
  • extracts such as, for example, horseradish oil, garlic extract, onion oil, black pepper, cayenne pepper, ginger oil, thyme oil, cinnamon bark oil, turmeric, fenugreek, cardamom, rosemary extract, grapefruit oil and andrographis extract.
  • the one or more strength enhancers or additives may include at least one of these extracts.
  • the one or more strength enhancers or additives may include one or more compounds that activate receptors in the respiratory system of an adult vaper such as the transient receptor potential cation channel, subfamily A, member 1 (TRPA1), the transient receptor potential cation channel subfamily V member 1 (TPRV1), or the nicotinic-acetylcholine receptors in an adult vaper, the agonists becoming part of the vapor and are carried in the respiratory tract of the adult vaper during vaping.
  • TRPA1 transient receptor potential cation channel, subfamily A, member 1
  • TPRV1 transient receptor potential cation channel subfamily V member 1
  • nicotinic-acetylcholine receptors in an adult vaper
  • the one or more strength enhancers or additives may include one or more of the above-listed compounds, among others, in a composition range of between about 0.0001 percent and about 1 percent, or in concentrations of up to about 2 percent.
  • concentration of the one or more strength enhancers or additives may be greater than about 2 percent when several strength enhancers are used in combination.
  • the total concentration of strength enhancers may be up to about 5 percent.
  • One or more acids are included in the pre-vaporization formulation in order to achieve a desired balance of increased strength and decreased harshness in an e-vaping device.
  • the one or more strength enhancers or additives increase the strength of the e-vaping device without increasing the delivery of nicotine and without increasing the harshness of the e-vaping article.
  • the pre-vaporization formulation may comprise nicotine in an amount of between about 0.5 percent and about 2 percent by weight or greater, or between about 0.5 percent and about 5 percent or greater.
  • the vapor formed by the vapor former includes a gas phase and a particulate phase, and the concentration of nicotine in the vapor phase is less than or equal to about 1 percent.
  • the pre-vaporization formulation according to the present invention includes one or more acids in a concentration of between about 0.1 percent and about 5 percent.
  • the one or more acids may have a boiling point of at least about 100 degrees Celsius and be configured to volatilize when heated by a heater in the e-vaping device.
  • the pre-vaporization formulation may be configured to form a vapor having a particulate phase and a gas phase when heated by the heater in the e-vaping device, the particulate phase containing protonated nicotine and the gas phase containing unprotonated nicotine.
  • the vapor has a majority amount of the protonated nicotine and a minority amount of the unprotonated nicotine.
  • the pre-vaporization formulation is configured to form a vapor having a nicotine gas phase component upon operation of the e-vaping device.
  • the acid may be included in an amount sufficient to reduce the nicotine gas phase component by about 70 percent or greater.
  • the addition of one or more acids may reduce the gas phase nicotine content by an amount in the range of between about 40 percent and about 70 percent by weight, or in the range of between about 40 percent and about 90 percent by weight.
  • the acid may be selected to have a liquid to vapor transfer efficiency of about 50 percent or greater.
  • the acid may be present in an amount sufficient to reduce the nicotine gas phase component.
  • the one or more acids include at least one of pyruvic acid, formic acid, oxalic acid, glycolic acid, acetic acid, isovaleric acid, valeric acid, propionic acid, octanoic acid, lactic acid, sorbic acid, malic acid, tartaric acid, succinic acid, citric acid, benzoic acid, oleic acid, aconitic acid, butyric acid, cinnamic acid, decanoic acid, 3,7-dimethyl-6-octenoic acid, 1-glutamic acid, heptanoic acid, hexanoic acid, 3-hexenoic acid, trans-2-hexenoic acid, isobutyric acid, lauric acid, 2-methylbutyric acid, 2-methylvaleric acid, myristic acid, nonanoic acid, palmitic acid, 4-pentenoic acid, phenylacetic acid, 3-phenylpropionic acid, hydrochloric
  • the acid includes pyruvic acid, lactic acid, benzoic acid and acetic acid.
  • the vapor former may include propylene glycol and glycerol or glycerin.
  • the vapor former may include substantially equal concentrations of propylene glycol and glycerol or glycerin.
  • the pre-vaporization formulation may include water in a concentration of between about 10 percent and about 20 percent.
  • An e-vaping device may include a first section and a second section.
  • the first section includes a pre-vaporization formulation reservoir including a pre-vaporization formulation according to the present invention such as, for example, a liquid material, a heater, a wick in communication with the pre-vaporization formulation reservoir and in communication with the heater, a mouth-end piece, and a connector at a distal end of the first section.
  • the second section includes a power supply, and a connector at a proximal end of the second section configured to matingly connect with the connector of the first section.
  • the first section may be a cartomizer.
  • the first section includes a pre-vaporization formulation reservoir including a pre-vaporization formulation according to the present invention, a heater, and a mouth end piece.
  • the heater is configured to heat the pre-vaporization formulation.
  • the second section may be a power supply section.
  • the second section includes a power source configured to supply power to the heater..
  • the first section may comprise a wick in communication with the pre-vaporization formulation reservoir and in communication with the heater.
  • the first section may comprise a connector at a distal end of the first section.
  • the second section may include a puff sensor configured to sense a puff taking place at the mouth-end piece.
  • the second section may comprise a connector at a proximal end of the second section configured to matingly connect with the connector of the first section.
  • first, second, third, and so forth may be used herein to describe various elements, components, regions, layers or sections, these elements, components, regions, layers, or sections should not be limited by these terms. These terms are only used to distinguish one element, component, region, layer, or section from another element, component, region, layer, or section. Therefore, a first element, component, region, layer, or section discussed below could be termed a second element, component, region, layer, or section without departing from the teachings of example embodiments.
  • spatially relative terms for example, “beneath,” “below,” “lower,” “above,” “upper,” and the like
  • the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if the device in the figures is turned over, elements described as “below” or “beneath” other elements or features would then be oriented “above” the other elements or features. Therefore, the term “below” may encompass both an orientation of above and below.
  • the device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly.
  • Example embodiments are described herein with reference to cross-sectional illustrations that are schematic illustrations of idealized embodiments (and intermediate structures) of example embodiments. As such, variations from the shapes of the illustrations as a result, for example, of manufacturing techniques or tolerances, are to be expected. Therefore, example embodiments should not be construed as limited to the shapes of regions illustrated herein but are to include deviations in shapes that result, for example, from manufacturing. Therefore, the regions illustrated in the figures are schematic in nature and their shapes are not intended to illustrate the actual shape of a region of a device and are not intended to limit the scope of example embodiments.
  • vapor former describes any suitable known compound or mixture of compounds that, in use, facilitates formation of a vapor and that is substantially resistant to thermal degradation at the operating temperature of the e-vaping device.
  • Suitable vapor-formers consist of various compounds such as, for example, polyhydric alcohols including at least one of propylene glycol, and glycerol or glycerin.
  • the vapor former is propylene glycol.
  • Fig. 1 is a side view of an e-vaping device 60, according to an example embodiment.
  • the e-vaping device 60 includes a first section or cartomizer 70 and a second section 72, which are coupled together at a threaded joint 74 or by other connecting structure such as one or more of a snug-fit, snap-fit, detent, clamp or clasp or the like.
  • the first section or cartomizer 70 may be a replaceable cartridge and the second section 72 may be a reusable section.
  • the first section or cartomizer 70 and the second section 72 may be integrally formed in one piece.
  • Fig. 2 is a cross-sectional view of an example embodiment of an e-vaping device.
  • the first section or cartomizer 70 can house a mouth-end insert 20, a capillary vapor generator including a capillary tube 18, a heater 19 to heat at least a portion of the capillary tube 18, and a reservoir 14.
  • the second section 72 can house a power supply 12, a control circuitry 11 configured to control the power supply 12, and a puff sensor 16.
  • the puff sensor is configured to sense when an adult vaper is puffing on the e-vaping device 60, which triggers operation of the power supply 12 via the control circuitry 11 to activate the heater 19 to heat the pre-vaporization formulation housed in the reservoir 14 and form a vapor.
  • a threaded portion 74 of the second section 72 can be connected to a battery charger, when not connected to the first section or cartomizer 70, to charge the battery or power supply 12.
  • a valve 40 can be a two-way valve, and the reservoir 14 can be pressurized.
  • the reservoir 14 can be pressurized using a pressurization arrangement 405 configured to apply constant pressure to the reservoir 14. As such, emission of vapor formed via heating of the pre-vaporization formulation housed in the reservoir 14 is facilitated.
  • the capillary tube 18 is formed of or includes a conductive material, and therefore acts as its own heater 19 by passing current through the tube.
  • the capillary tube 18 may be any electrically conductive material capable of being resistively heated, while retaining the necessary structural integrity at the operating temperatures experienced by the capillary tube 18, and which is non-reactive with the pre-vaporization formulation.
  • Suitable materials for forming the capillary tube 18 are one or more of stainless steel, copper, copper alloys, porous ceramic materials coated with film resistive material, nickel-chromium alloys, and combinations thereof.
  • the capillary tube 18 is a stainless steel capillary tube 18 and serves as a heater 19 via electrical leads 26 attached thereto for passage of direct or alternating current along a length of the capillary tube 18. Therefore, the stainless steel capillary tube 18 is heated by resistance heating.
  • the capillary tube 18 may be a non-metallic tube such as, for example, a glass tube.
  • the heater 19 is formed of or includes a conductive material capable of being resistively heated, such as, for example, stainless steel, nichrome or platinum wire, arranged along the glass tube. When the heater arranged along the glass tube is heated, pre-vaporization formulation in the capillary tube 18 is heated to a temperature sufficient to at least partially volatilize pre-vaporization formulation in the capillary tube 18.
  • At least two electrical leads 26 are bonded to the metallic capillary tube 18.
  • one electrical lead 26 is coupled to a first, upstream portion 101 of the capillary tube 18 and a second electrical lead 26 is coupled to a downstream, end portion 102 of the capillary tube 18.
  • the puff sensor 16 detects a pressure gradient caused by the puffing of the adult vaper, and the control circuitry 11 activates the heater 19 to heat the pre-vaporization formulation located in the reservoir 14.
  • the pre-vaporization formulation contained within a heated portion of the capillary tube 18 is volatilized and expressed out of the outlet 63, where the pre-vaporization formulation expands and mixes with air and forms a vapor in mixing chamber 240.
  • the power supply 12 of example embodiments can include a battery arranged in the second section 72 of the e-vaping device 60.
  • the power supply 12 is configured to apply voltage across the heater 19, and the heater 19 volatilizes the pre-vaporization formulation housed in the reservoir 14.
  • the electrical contacts or connection between the heater 19 and the electrical leads 26 are substantially conductive and temperature resistant while the heater 19 is substantially resistive so that heat generation occurs primarily along the heater 19 and not at the contacts.
  • the power supply or battery 12 may be rechargeable and include circuitry allowing the battery to be chargeable by an external charging device.
  • the circuitry when charged, provides power for a pre-determined number of puffs, after which the circuitry may have to be re-connected to an external charging device.
  • the e-vaping device 60 may include control circuitry which can be on a printed circuit board 11.
  • the control circuitry 11 may also include a heater activation light 27 that is configured to glow when the heater 19 is activated.
  • the heater activation light 27 comprises at least one LED and is at a distal end 28 of the e-vaping device 60 so that the heater activation light 27 illuminates a cap which takes on the appearance of a burning coal during a puff.
  • the heater activation light 27 can be configured to be visible to the adult vaper.
  • the light 27 may also be configured such that the adult vaper can activate, deactivate, or activate and deactivate the light 27 when desired, such that the light 27 would not activate during vaping if desired.
  • the e-vaping device 60 further includes a mouth-end insert 20 having at least two off-axis, diverging outlets 21.
  • the mouth-end insert 20 includes at least two diverging outlets 21 (for example, 3 to 8 outlets or more).
  • the outlets 21 of the mouth-end insert 20 are located at ends of off-axis passages 23 and are angled outwardly in relation to the longitudinal direction of the e-vaping device 60 (that is, divergently).
  • the term "off-axis" denotes an angle to the longitudinal direction of the e-vaping device.
  • the mouth-end insert (or flow guide) 20 may include outlets uniformly distributed around the mouth-end insert 20 so as to substantially uniformly distribute vapor in an adult vaper's mouth during use.
  • the e-vaping device 60 is about the same size as a conventional cigarette. In some embodiments, the e-vaping device 60 may be about 80 millimeters to about 110 millimeters long, for example about 80 millimeters to about 100 millimeters long and about 7 millimeters to about 10 millimeters in diameter.
  • the outer cylindrical housing 22 of the e-vaping device 60 may be formed of or include any suitable material or combination of materials.
  • the outer cylindrical housing 22 is formed at least partially of metal and is part of the electrical circuit connecting the control circuitry 11, the power supply 12, the puff sensor 16 and the heater 19.
  • Fig. 3 is a cross-sectional view of an e-vaping device according to an example embodiment.
  • the e-vaping device 60 can also include a middle section (third section) 73, which can house the liquid pre-vaporization formulation reservoir 14 and the heater 19.
  • the middle section 73 can be configured to be fitted with a threaded joint 74' at an upstream end of the first section or cartomizer 70 and a threaded joint 74 at a downstream end of the second section 72.
  • the first section or cartomizer 70 houses the mouth-end insert 20, while the second section 72 houses the power supply 12 and the control circuitry 11 that is configured to control the power supply 12.
  • the first section or cartomizer 70, the second section 72 and the third section 73 include a common outer cylindrical housing 22 extending in a longitudinal direction along the length of the e-vaping device 60.
  • the middle section 73 is disposable and one or both of the first section or cartomizer 70 and the second section 72 are reusable.
  • the sections 70, 72, 73 can be attached by threaded connections or connectors 74 and 74' whereby the middle section 73 can be replaced when the reservoir 14 is used up.
  • the first section or cartomizer 70 is replaceable so as to avoid the need for cleaning one or both of the capillary tube 18 and the heater 19.
  • the first section or cartomizer 70, the second section 72 and the middle section 73 may be integrally formed without threaded connections to form a disposable e-vaping device.
  • the reservoir 14 is a tubular, elongated body formed of or including an elastomeric material so as to be one or both of flexible and compressible when squeezed.
  • the elastomeric material can be one of silicone, plastic, rubber, latex, and combinations thereof.
  • the reservoir 14 is in fluid communication with a capillary tube 18 so that when squeezed, the reservoir 14 can deliver a volume of a pre-vaporization formulation such as a liquid material to the capillary tube 18.
  • a pre-vaporization formulation such as a liquid material
  • the power supply 12 is activated upon the application of the manual pressure on the reservoir 14, and the capillary tube 18 is heated to form a heated section wherein the pre-vaporization formulation is volatilized.
  • the volatilized material expands, mixes with air and forms a vapor.
  • the reservoir 14 includes a valve 40 configured to maintain the liquid pre-vaporization formulation within the reservoir 14 and to open when the reservoir 14 is squeezed and pressure is applied to the reservoir 14.
  • the valve 40 opens when a critical, minimum pressure is reached so as to avoid inadvertent dispensing pre-vaporization formulation from the reservoir 14 or activating the heater 19.
  • the pressure required to press the pressure switch 44 is high enough such that accidental heating is avoided. Such arrangement avoids activation of the heater 19 in the absence of pre-vaporization formulation being pumped through the capillary.
  • valve 40 closes and the heated capillary tube 18 discharges any pre-vaporization formulation remaining downstream of the valve 40.
  • the strength enhancers or additives may include cinnamaldehyde, menthone, eugenol, zingerone or vanillyacetone, and gingerol.
  • the strength enhancers may also include capsicum, allyl isothiocyanate, piperine, isoeugenol, menthol.
  • the strength enhancers include one or more compounds that activate receptors in the respiratory system of an adult vaper such as the transient receptor potential cation channel, subfamily A, member 1 (TRPA1), the transient receptor potential cation channel subfamily V member 1 (TPRV1), or the nicotinic-acetylcholine receptor agonists in an adult vaper, the receptors becoming part of the particulate phase and are carried in the respiratory tract of the adult vaper with the particulate phase during vaping.
  • TRPA1 transient receptor potential cation channel, subfamily A, member 1
  • TPRV1 transient receptor potential cation channel subfamily V member 1
  • nicotinic-acetylcholine receptor agonists in an adult vaper, the receptors becoming part of the particulate phase and are carried in the respiratory tract of the adult vaper with the particulate phase during vaping.
  • the above compounds as well as others can be found in extracts such as, for example, horseradish oil, garlic extract, onion oil, black pepper, cayenne pepper, ginger oil, thyme oil, cinnamon bark oil, turmeric, fenugreek, cardamom, rosemary extract, grapefruit oil and andrographis extract.
  • extracts such as, for example, horseradish oil, garlic extract, onion oil, black pepper, cayenne pepper, ginger oil, thyme oil, cinnamon bark oil, turmeric, fenugreek, cardamom, rosemary extract, grapefruit oil and andrographis extract.
  • the pre-vaporization formulation may include one or more strength enhancers in a composition range of between about 0.0001 percent and about 1 percent, in concentrations of up to about 2 percent, or in concentrations of more than about 2 percent and less than about 5 percent when the strength enhancer is a combination of a plurality of strength enhancers. These strength enhancers may activate receptors in the respiratory system of an adult vaper.
  • the pre-vaporization formulation optionally includes water.
  • Water may be included in an amount ranging from about 5 percent by weight based on the weight of the pre-vaporization formulation to about 40 percent by weight based on the weight of the pre-vaporization formulation. For example, water may be included at about 20 percent by weight based on the weight of the pre-vaporization formulation.
  • the amount of nicotine in the various formulations may be between about 0.5 percent and about 1.5 percent or between about 0.5 percent and about 2 percent.
  • the various strength enhancers are discussed above.
  • the acid discussed below includes at least one of pyruvic acid, formic acid, oxalic acid, glycolic acid, acetic acid, isovaleric acid, valeric acid, propionic acid, octanoic acid, lactic acid, sorbic acid, malic acid, tartaric acid, succinic acid, citric acid, benzoic acid, oleic acid, aconitic acid, butyric acid, cinnamic acid, decanoic acid, 3,7-dimethyl-6-octenoic acid, 1-glutamic acid, heptanoic acid, hexanoic acid, 3-hexenoic acid, trans-2-hexenoic acid, isobutyric acid, lauric acid, 2-methylbutyric acid, lauric acid, 2-methylbutyric acid
  • the acid is operative upon the vapor generated from the pre-vaporization formulation upon operation of the e-vaping device so as to reduce the amount of perceived throat harshness, while the strength enhancer is operative upon the vapor to increase the perceived strength of the vapor.
  • the acid has the capacity to transfer into a vaporized formulation.
  • Liquid to vapor transfer efficiency of an acid is the ratio of the mass fraction of the acid in the vaporized formulation to the mass fraction of the acid in the pre-vaporization formulation.
  • the acid has a pre-vaporization formulation such as a liquid to vapor transfer efficiency of about 50 percent or greater, for example about 60 percent or greater.
  • a liquid to vapor transfer efficiency of about 50 percent or greater.
  • pyruvic acid, lactic acid, oxalic acid, acetic acid and glycolic acid have a liquid to vapor transfer efficiency of about 50 percent or greater.
  • the pre-vaporization formulation includes an acid having a liquid to vapor transfer efficiency of about 50 percent or greater.
  • the pre-vaporization formulation excludes any acid having a liquid to vapor transfer efficiency of about 25 percent or less.
  • the acid has a boiling point of at least about 100 degrees Celsius, and may be included in the pre-vaporization formulation in an amount sufficient to adjust the pH of the pre-vaporization formulation in the range of about 3 to about 8.
  • the pre-vaporization formulation includes one or more of pyruvic acid, formic acid, oxalic acid, glycolic acid, acetic acid, isovaleric acid, valeric acid, propionic acid, octanoic acid, lactic acid, sorbic acid, malic acid, tartaric acid, succinic acid, citric acid, benzoic acid, oleic acid, aconitic acid, butyric acid, cinnamic acid, decanoic acid, 3,7-dimethyl-6-octenoic acid, 1-glutamic acid, heptanoic acid, hexanoic acid, 3-hexenoic acid, trans-2-hexenoic acid, isobutyric acid, lauric acid, 2-methylbutyric acid, 2-methylvaleric acid, myristic acid, nonanoic acid, palmitic acid, 4-pentenoic acid, phenylacetic acid, 3-phenylpropionic acid, hydro

Landscapes

  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Botany (AREA)
  • Medicinal Preparation (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Junction Field-Effect Transistors (AREA)
  • Physical Vapour Deposition (AREA)
  • Catching Or Destruction (AREA)
EP16822652.0A 2015-12-18 2016-12-16 Strength enhancers and method of achieving strength enhancement in an electronic vapor device Active EP3389420B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL16822652T PL3389420T3 (pl) 2015-12-18 2016-12-16 Wzmacniacze mocy i sposoby wzmacniające moc w elektronicznym urządzeniu waporyzującym

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/974,211 US20170172204A1 (en) 2015-12-18 2015-12-18 Strength enhancers and method of achieving strength enhancement in an electronic vapor device
PCT/EP2016/081469 WO2017103136A1 (en) 2015-12-18 2016-12-16 Strength enhancers and method of achieving strength enhancement in an electronic vapor device

Publications (2)

Publication Number Publication Date
EP3389420A1 EP3389420A1 (en) 2018-10-24
EP3389420B1 true EP3389420B1 (en) 2019-09-11

Family

ID=57749910

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16822652.0A Active EP3389420B1 (en) 2015-12-18 2016-12-16 Strength enhancers and method of achieving strength enhancement in an electronic vapor device

Country Status (12)

Country Link
US (1) US20170172204A1 (es)
EP (1) EP3389420B1 (es)
JP (2) JP2019503660A (es)
KR (1) KR20180094868A (es)
CN (1) CN108289496A (es)
CA (1) CA3001780A1 (es)
ES (1) ES2749951T3 (es)
IL (1) IL259200B2 (es)
MX (1) MX2018006898A (es)
PL (1) PL3389420T3 (es)
RU (1) RU2730706C2 (es)
WO (1) WO2017103136A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10244793B2 (en) 2005-07-19 2019-04-02 Juul Labs, Inc. Devices for vaporization of a substance
US10279934B2 (en) 2013-03-15 2019-05-07 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
USD825102S1 (en) 2016-07-28 2018-08-07 Juul Labs, Inc. Vaporizer device with cartridge
USD842536S1 (en) 2016-07-28 2019-03-05 Juul Labs, Inc. Vaporizer cartridge
US10159282B2 (en) 2013-12-23 2018-12-25 Juul Labs, Inc. Cartridge for use with a vaporizer device
CN110638109B (zh) 2013-12-23 2023-08-18 尤尔实验室有限公司 蒸发装置系统和方法
US10058129B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Vaporization device systems and methods
US10076139B2 (en) 2013-12-23 2018-09-18 Juul Labs, Inc. Vaporizer apparatus
US20160366947A1 (en) 2013-12-23 2016-12-22 James Monsees Vaporizer apparatus
CN112155255A (zh) 2014-12-05 2021-01-01 尤尔实验室有限公司 校正剂量控制
CO2018009342A2 (es) 2016-02-11 2018-09-20 Juul Labs Inc Cartuchos de fijación segura para dispositivos vaporizadores
SG11201806793TA (en) 2016-02-11 2018-09-27 Juul Labs Inc Fillable vaporizer cartridge and method of filling
US10405582B2 (en) 2016-03-10 2019-09-10 Pax Labs, Inc. Vaporization device with lip sensing
USD849996S1 (en) 2016-06-16 2019-05-28 Pax Labs, Inc. Vaporizer cartridge
USD836541S1 (en) 2016-06-23 2018-12-25 Pax Labs, Inc. Charging device
USD851830S1 (en) 2016-06-23 2019-06-18 Pax Labs, Inc. Combined vaporizer tamp and pick tool
JP6882507B2 (ja) 2016-12-02 2021-06-02 ブイエムアール・プロダクツ・リミテッド・ライアビリティ・カンパニーＶｍｒ Ｐｒｏｄｕｃｔｓ Ｌｌｃ 混合式ヴェポライザ
CA3044615A1 (en) * 2016-12-29 2018-07-05 Jt International S.A. Tobacco mousse
CN107343668A (zh) * 2017-08-31 2017-11-14 云南巴菰生物科技有限公司 一种提升香气质感的电子烟油及其制备方法与它的用途
USD887632S1 (en) 2017-09-14 2020-06-16 Pax Labs, Inc. Vaporizer cartridge
GB201807305D0 (en) * 2018-05-03 2018-06-20 Nicoventures Trading Ltd Vaporisable formulation
GB201817859D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolisable formulation
CN109619655A (zh) * 2019-01-18 2019-04-16 深圳市同信兴投资有限公司 一种复合尼古丁盐及其溶液、其制备方法及应用
FR3093405B1 (fr) * 2019-03-05 2022-07-29 V F P France Compositions de vapotage
WO2020259977A1 (en) * 2019-06-25 2020-12-30 Philip Morris Products S.A. Cartridge comprising nicotine and a water-immiscible solvent
FR3110347B1 (fr) 2020-05-20 2022-06-03 V F P France Compositions de vapotage
CN114468345B (zh) * 2021-12-28 2022-11-15 四川三联新材料有限公司 一种具有花椒风味的电子烟烟液及其制备方法
CN115119957A (zh) * 2022-06-28 2022-09-30 深圳市艾普生物科技有限公司 一种抗氧化电子烟油及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009001085A2 (en) 2007-06-25 2008-12-31 Kind Consumer Limited An inhalable composition comprising nicotine
WO2013090410A1 (en) 2011-12-14 2013-06-20 Sentiens, Llc Device and method for simulating chemosensation of smoking
WO2014182736A1 (en) 2013-05-06 2014-11-13 Ploom, Inc. Nicotine salt formulations for aerosol devices and methods thereof
US20150038576A1 (en) 2013-08-02 2015-02-05 Sentiens, Llc Compositions and their use for smoking cessation and other treatments
EP2862454A1 (de) 2013-10-18 2015-04-22 Valeo Laboratories GmbH Flüssige Zusammensetzung für eine elektronische Zigarette
WO2015084544A1 (en) 2013-12-05 2015-06-11 Ploom, Inc. Nicotine liquid formulations for aerosol devices and methods thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62175896U (es) * 1986-04-25 1987-11-09
CN1124126C (zh) * 1995-08-29 2003-10-15 威·曼父子有限公司 清凉剂组合物
AU6246099A (en) * 1998-09-17 2000-04-03 Wei-Hsin Hou Cigarette filter made from surface activated particulate particles
ES2288701T3 (es) * 2003-11-04 2008-01-16 Firmenich Sa Ingredientes de sabor para preparaciones refrescantes.
US20080038386A1 (en) * 2006-08-02 2008-02-14 Ashok K Moza Use of a liquid cooling sensate to provide a pungent, warming or tingling sensate composition
CN111084419B (zh) * 2012-04-30 2023-03-17 菲利普莫里斯生产公司 具有凉爽剂包络物的吸烟制品烟嘴
US20140261486A1 (en) * 2013-03-12 2014-09-18 R.J. Reynolds Tobacco Company Electronic smoking article having a vapor-enhancing apparatus and associated method
MY179801A (en) * 2013-07-19 2020-11-16 Altria Client Services Llc Liquid aerosol formulation of an electronic smoking article
US9877511B2 (en) * 2013-07-24 2018-01-30 Altria Client Services Llc Electronic smoking article
KR102609456B1 (ko) * 2014-02-10 2023-12-05 필립모리스 프로덕츠 에스.에이. 히터 조립체를 포함하고 있는 에어로졸 발생 시스템용 카트리지

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009001085A2 (en) 2007-06-25 2008-12-31 Kind Consumer Limited An inhalable composition comprising nicotine
WO2013090410A1 (en) 2011-12-14 2013-06-20 Sentiens, Llc Device and method for simulating chemosensation of smoking
WO2014182736A1 (en) 2013-05-06 2014-11-13 Ploom, Inc. Nicotine salt formulations for aerosol devices and methods thereof
US20150038576A1 (en) 2013-08-02 2015-02-05 Sentiens, Llc Compositions and their use for smoking cessation and other treatments
EP2862454A1 (de) 2013-10-18 2015-04-22 Valeo Laboratories GmbH Flüssige Zusammensetzung für eine elektronische Zigarette
WO2015084544A1 (en) 2013-12-05 2015-06-11 Ploom, Inc. Nicotine liquid formulations for aerosol devices and methods thereof

Also Published As

Publication number Publication date
CN108289496A (zh) 2018-07-17
PL3389420T3 (pl) 2020-06-15
KR20180094868A (ko) 2018-08-24
IL259200B2 (en) 2023-09-01
CA3001780A1 (en) 2017-06-22
US20170172204A1 (en) 2017-06-22
RU2018125249A (ru) 2020-01-20
ES2749951T3 (es) 2020-03-24
IL259200B1 (en) 2023-05-01
JP2022103338A (ja) 2022-07-07
IL259200A (en) 2018-07-31
WO2017103136A1 (en) 2017-06-22
JP2019503660A (ja) 2019-02-14
EP3389420A1 (en) 2018-10-24
RU2730706C2 (ru) 2020-08-25
RU2018125249A3 (es) 2020-04-14
MX2018006898A (es) 2018-09-06

Similar Documents

Publication Publication Date Title
EP3389420B1 (en) Strength enhancers and method of achieving strength enhancement in an electronic vapor device
KR102667573B1 (ko) 전자 흡연 장치에서 산도를 제어하기 위한 기화전 제제
RU2706839C2 (ru) Жидкий состав для электронного устройства для парения
US11337453B2 (en) Liquid aerosol formulation of an electronic smoking article
US20150313275A1 (en) Liquid aerosol formulation of an electronic smoking article
EP3641571B1 (en) Encapsulated ingredients for e-vaping devices and method of manufacturing thereof
JP7258761B2 (ja) ｅベイピング装置の動作中に有機酸を形成するためのプレベイパー製剤

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180615

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190410

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1177330

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190915

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016020593

Country of ref document: DE

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: VENI GMBH, CH

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20191126

Year of fee payment: 4

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191212

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2749951

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20200324

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1177330

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200113

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20200121

Year of fee payment: 4

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200224

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602016020593

Country of ref document: DE

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: NICOVENTURES TRADING LIMITED

Effective date: 20200609

PG2D Information on lapse in contracting state deleted

Ref country code: IS

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200112

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20191231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191216

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191216

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20161216

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220209

REG Reference to a national code

Ref country code: DE

Ref legal event code: R100

Ref document number: 602016020593

Country of ref document: DE

PLCK Communication despatched that opposition was rejected

Free format text: ORIGINAL CODE: EPIDOSNREJ1

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

PLBN Opposition rejected

Free format text: ORIGINAL CODE: 0009273

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: OPPOSITION REJECTED

27O Opposition rejected

Effective date: 20220310

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230529

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231220

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20231220

Year of fee payment: 8

Ref country code: IT

Payment date: 20231221

Year of fee payment: 8

Ref country code: FR

Payment date: 20231222

Year of fee payment: 8

Ref country code: DE

Payment date: 20231214

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20231218

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240101

Year of fee payment: 8